Johnson & Johnson has announced that Zytiga (abiraterone acetate) in combination with prednisone has been awarded FDA approval in the treatment of metastatic high-risk castration-sensitive prostate cancer (CSPC).
FDA expands J&J Zytiga combo’s indication to include castration-sensitive prostate cancer
